SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 32.36 |
| Enterprise Value ($M) | 2.23 |
| Book Value ($M) | 27.75 |
| Book Value / Share | 1.05 |
| Price / Book | 1.17 |
| NCAV ($M) | 26.21 |
| NCAV / Share | 1.00 |
| Price / NCAV | 1.23 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.76 |
| Return on Assets (ROA) | -0.25 |
| Return on Equity (ROE) | -0.50 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 4.40 |
| Current Ratio | 4.40 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 79.30 |
| Assets | 80.83 |
| Liabilities | 53.09 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 11.98 |
| Operating Income | -29.69 |
| Net Income | -25.11 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -19.54 |
| Cash from Investing | 12.47 |
| Cash from Financing | -0.57 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | BML Investment Partners, L.P. | 7.40 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 14,535 | 101,668 | 14.30 | |
| 11,079 | 105,430 | 10.51 | |
| 1,582 | 6,073 | 26.05 | |
| 4,412 | 71,513 | 6.17 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| KRYS – Krystal Biotech, Inc. | KURA – Kura Oncology, Inc. |
| KYTX – Kyverna Therapeutics, Inc. | LXRX – Lexicon Pharmaceuticals, Inc. |
| LYEL – Lyell Immunopharma, Inc. |
Financial data and stock pages provided by
Fintel.io